Now trading at a price of $68.48, CVS Health has moved 0.0% so far today.
CVS Health returned losses of -32.0% last year, with its stock price reaching a high of $104.83 and a low of $64.41. Over the same period, the stock underperformed the S&P 500 index by -47.0%. As of April 2023, the company's 50-day average price was $69.47. CVS Health Corporation provides health services in the United States. Based in Woonsocket, RI, the large-cap Consumer Staples company has 219,000 full time employees. CVS Health has offered a 3.5% dividend yield over the last 12 months.
Growing Revenues With Increasing Reinvestment in the Business:
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (MM) | $194,579 | $256,776 | $268,706 | $292,111 | $322,467 | $347,809 |
| Revenue Growth | n/a | 31.96% | 4.65% | 8.71% | 10.39% | 7.86% |
| Operating Margins | 2% | 5% | 5% | 5% | 2% | 4% |
| Net Margins | 0% | 3% | 3% | 3% | 1% | 2% |
| Net Income (MM) | -$2 | $6,634 | $7,192 | $8,001 | $4,327 | $8,653 |
| Net Interest Expense (MM) | $2,803 | $3,035 | $2,907 | $2,503 | $2,287 | $2,520 |
| Depreciation & Amort. (MM) | $2,718 | $4,371 | $4,441 | $4,486 | $4,224 | $4,275 |
| Earnings Per Share | -$0.57 | $5.08 | $5.46 | $6.02 | $3.26 | $6.67 |
| EPS Growth | n/a | 991.23% | 7.48% | 10.26% | -45.85% | 104.6% |
| Diluted Shares (MM) | 1,044 | 1,305 | 1,314 | 1,329 | 1,323 | 1,227 |
| Free Cash Flow (MM) | $6,828 | $10,391 | $13,428 | $15,745 | $13,450 | $11,302 |
| Capital Expenditures (MM) | $2,037 | $2,457 | $2,437 | $2,520 | $2,727 | $2,808 |
| Current Ratio | 1.03 | 0.94 | 0.91 | 0.89 | 0.95 | 0.86 |
| Long Term Debt (MM) | $71,444 | $64,699 | $96,646 | $88,585 | $80,355 | $59,782 |
| Net Debt / EBITDA | 13.62 | 5.03 | 6.75 | 5.83 | 7.27 | 4.18 |
CVS Health Has Attractive Multiples and Trades Below Its Graham Number:
CVS Health has a trailing twelve month P/E ratio of 10.6, compared to an average of 21.21 for the Consumer Staples sector. Based on its EPS guidance of $8.51, the company has a forward P/E ratio of 8.2. The company doesn't provide forward earnings guidance, and the compound average growth rate of its last 6 years of reported EPS is 52.7%. On this basis, CVS Health's PEG ratio is 0.2. Using instead the 11.3% weighted average of CVS Health's earnings CAGR and the broader market's anticipated 5-year EPS growth rate, the company's PEG ratio is 0.94, which implies that its shares may be underpriced. Additionally, the market is possibly undervaluing CVS Health in terms of its equity because its P/B ratio is 1.19 whereas the sector average is 4.12. The company's shares are currently trading -28.2% below their Graham number.
Analysts Give CVS Health an Average Rating of Buy:
The 22 analysts following CVS Health have set target prices ranging from $74.0 to $104.0 per share, for an average of $86.82 with a buy rating. As of April 2023, the company is trading -20.0% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
CVS Health has a very low short interest because 1.2% of the company's shares are sold short. Institutions own 79.9% of the company's shares, and the insider ownership rate stands at 0.18%, suggesting a small amount of insider investors. The largest shareholder is Vanguard Group Inc, whose 9% stake in the company is worth $8,023,297,021.
